For Q1 of the fiscal year ending March 2027, consolidated net sales were 289,401 million yen (up 5.8% YoY), operating income was 22,673 million yen (up 27.7% YoY), ordinary income was 24,790 million yen (up 37.8% YoY), and net income attributable to owners of the parent was 15,271 million yen (up 51.3% YoY). Full-year guidance unchanged. Segments: both foods and pharmaceuticals remained solid, with pharmaceuticals benefiting from new product promotions and overseas revenue contributions. Preparation of the supplementary materials for the earnings release and a briefing session are planned.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2269","jir_company_name":"Meiji Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/2269-20260805-01.pdf","jir_short_summary":"For Q1 of the fiscal year ending March 2027, consolidated net sales were 289,401 million yen (up 5.8% YoY), operating income was 22,673 million yen (up 27.7% YoY), ordinary income was 24,790 million yen (up 37.8% YoY), and net income attributable to owners of the parent was 15,271 million yen (up 51.3% YoY). Full-year guidance unchanged. Segments: both foods and pharmaceuticals remained solid, with pharmaceuticals benefiting from new product promotions and overseas revenue contributions. Preparation of the supplementary materials for the earnings release and a briefing session are planned.","jir_summary":"### Business Performance Overview\nFor the Q1 of the fiscal year ending March 2027, consolidated net sales reached 289,401 million yen, up 5.8% YoY, operating income was 22,673 million yen, up 27.7% YoY, ordinary income was 24,790 million yen, up 37.8% YoY, and net income attributable to owners of the parent was 15,271 million yen, up 51.3% YoY, marking substantial profit growth. Segments show solid performance in both foods and pharmaceuticals. Plans exist to prepare the earnings release supplementary materials and hold an analyst briefing.\n\n### Outlook and Points of Attention\nFull-year guidance remains unchanged from the time of the forecast. Remaining risks include currency and raw material cost movements and geopolitical factors. In the Pharmaceuticals segment, new product adoption and growth in plasma-derived products contribute to profits. In the Foods segment, higher raw material costs are being absorbed, and cost reduction and productivity improvements continue to take effect. Refer to the earnings briefing materials and appendices.","jir_financial_highlights":"Sales: 289,401\u767e\u4e07\u5186 (YoY +5.8%)\nOperating income: 22,673\u767e\u4e07\u5186 (YoY +27.7%)\nOrdinary income: 24,790\u767e\u4e07\u5186 (YoY +37.8%)\nNet income attributable to owners of the parent: 15,271\u767e\u4e07\u5186 (YoY +51.3%)\nEarnings per share: 56.33\u5186 (YoY)\nEquity ratio: 60.1% (YoY -1.1pp)","jir_category":"","jir_hashtags":"#MeijiHoldings, #IR, #JapaneseStocks","jir_key_figures":"Sales: 289,401\u767e\u4e07\u5186\nOperating income: 22,673\u767e\u4e07\u5186\nNet income attributable to owners of the parent: 15,271\u767e\u4e07\u5186","jir_meta_title":"Meiji Holdings: Q1 FY2027 Financial Results \u2014 Sales 289,401 million yen, Operating income 22,673 million yen","jir_meta_description":"Summary of Meiji Holdings' Q1 FY2027 results. Highlights of sales and profit trends, segment movements, whether the full-year outlook changed, and information on the earnings briefing.","jir_og_title":"Meiji Holdings Q1 FY2027 Earnings Highlights","jir_og_description":"Q1 FY2027 results show sales of 289,401 million yen and operating income of 22,673 million yen. Full-year guidance unchanged. Earnings briefing information available.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7598,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-95426","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n